Half Year 2025 Financial ResultsRevenue and Other Income: Revenue and other income have increased for the six months ended June 30, 2025, up to €26.6 million, compared to €9.3 million for the same period in 2024. Research and Development (“R&D”) Expenses: R&D expenses consist primarily of preclinical, clinical and manufacturing expenses including employee-related payroll expenses related to the development of JNJ-1900 (NBTXR3). These expenses for the six months ending June 30 2025, were €14.5 million compared to €22.0 million for the same period in 2024. Cash and Cash Equivalents: Cash and cash equivalents as of June 30, 2025, were €28.8 million, compared to €49.7 million as of December 31, 2024. Availability of the Half Year 2025 Financial ReportsThe 2025 half-year financial report has been filed with the French financial market authority (Autorité des marchés financiers).